

Special Issue

Genomics of Rare Hematologic Cancers

Message from the Guest Editor

Leukemias and hematologic cancers occur with less frequency than solid tumors. The most frequent and well-known hematologic cancers could be summarized in chronic and acute myeloid and lymphoid leukemias, myelomas and lymphomas, as well as myelodysplastic syndromes and myeloproliferative neoplasms. In this Special Issue we selected some of the rarest types of hematologic cancers because there are few reviews about these diseases. Now, genomics defines the diagnosis, prognosis, and treatment of most cancers, and we want to present a review of how genomics is useful to define these rare diseases. In this Special Issue we will highlight the genomic information that will be very useful for clinicians to diagnose and treat these patients.

Guest Editor

Dr. Francesc Solé

1. MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, 08916 Barcelona, Spain
2. Microarrays Unit, Institut de Recerca Contra la Leucèmia Josep Carreras, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain

Deadline for manuscript submissions

closed (15 June 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/81680

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)